The continuation of oral anticoagulation with a vitamin K antagonist during transcatheter aortic valve replacement (TAVR) did not increase bleeding or vascular complication rates, according to study results published in JACC: Cardiovascular Interventions.

In this study, researchers examined data from 5 high-volume European centers to compare safety and efficacy of continuation vs interruption of anticoagulant therapy before and after transfemoral TAVR.

A total of 4459 consecutive patients on oral anticoagulation who underwent transfemoral TAVR were included in this analysis. Oral anticoagulation was halted in 733 patients, 2 to 4 days before TAVR, and continued in 584 patients throughout TAVR. The study’s primary safety outcome was major bleeding. Secondary efficacy endpoints were vascular complications, stroke, and mortality.

Continue Reading

At the 30-day follow up, the incidence of major or life-threatening bleedings was 11.3% and 14.3% in patients who continued vs stopped oral anticoagulation, respectively (odds ratio [OR], 0.86; 95% CI, 0.61-1.21; P =.39). The incidence of major vascular complications was 11.0% vs 12.3% in the continuation and interruption groups, respectively (OR, 0.89; CI, 0.62-1.27; P =.52).

Patients who continued vs stopped anticoagulation therapy during TAVR often required less transfusion of packed red blood cells (13.7% vs 17.7%, respectively; OR, 0.59; 95% CI, 0.42-0.81; P =.001). Kaplan-Meier estimates of 12-month survival was comparable in the continuation and interruption groups (85.3% vs 84.0%, respectively; hazard ratio, 0.90; 95% CI, 0.73-1.12; P =.36).

Predictors of major or life-threatening bleeding included female sex (OR, 1.59; 95% CI, 1.14-2.23; P =.007), higher CHA2DS2-VASc score (OR, 1.218; 95% CI, 1.043-1.423; P =.013), higher Society of Thoracic Surgeons score (OR, 1.050; 95% CI, 1.020-1.081; P =.001), and lower baseline hemoglobin (OR, 0.98 per g/l; 95% CI, 0.981-0.995; P =.001) in multiple logistic regression analyses.

Limitations of this study include a nonrandomized design.

Based on their findings, the investigators of the study concluded that the “continuation of oral anticoagulation throughout TAVR appears to be safe and effective.”

Disclosure: Several study authors declared affiliations with the pharmaceutical industry. Please see the original reference for a full list of authors’ disclosures.


Brinkert M, Mangner N, Moriyama N, et al. Safety and efficacy of transcatheter aortic valve replacement with continuation of vitamin K antagonists or direct oral anticoagulants. Published online December 17, 2020. JACC Cardiovasc Interv. doi:10.1016/j.jcin.2020.09.062

This article originally appeared on The Cardiology Advisor